Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett, page-139

Agreed, as much as we want to know whats behind the curtain, telling the market might not be prudent for end shareholder value. Good for short term though... Maybe we need it to get some fair value reflected..

We might very well have enough evidence on FTO "validation" but is it beneficial giving this info to the market right now? it might excite investors but be detrimental to the strategy of selling the company for decent $$. Which is what we are all here for.

Not being a trial end point there's no need to announce, as much as we want to know. T
the value in keeping it under wraps until a patent is lodged totally makes sense - I think both Index & JP hit the nail on the head.

Given EMD had FTO validation as an endpoint and all going well we would have been expecting some sort of data around the same time, it would have been close to the right time to let it go to market if someone wanted to acquire us.